China Pharma Pure Powder manufacturer
Contact Us

Contact Person : Karen

Phone Number : 13892020662

WhatsApp : +8613892020662

Free call

Marbofloxacin 99% veterinary Medicine Cas 115550-35-1

September 18, 2021

Latest company news about Marbofloxacin 99% veterinary Medicine Cas 115550-35-1

Marboquin (marbofloxacin) Tablets

This page contains information on Marboquin (marbofloxacin) Tablets for veterinary use.
The information provided typically includes the following:
  • Marboquin (marbofloxacin) Tablets Indications
  • Warnings and cautions for Marboquin (marbofloxacin) Tablets
  • Direction and dosage information for Marboquin (marbofloxacin) Tablets

Marboquin (marbofloxacin) Tablets

This treatment applies to the following species:

Company: Dechra

For oral use in dogs and cats only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Federal law prohibits the extralabel use of this drug in food-producing animals.

Description

Marbofloxacin is a synthetic broad-spectrum antibacterial agent from the fluoroquinolone class of chemotherapeutic agents. Marbofloxacin is the non-proprietary designation for 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2] benzoxadiazine-6-carboxylic acid. The empirical formula is C17H19FN4O4 and the molecular weight is 362.36. The compound is soluble in water; however, solubility decreases in alkaline conditions. The N-octanol/water partition coefficient (Kow) is 0.835 measured at pH 7 and 25°C.

Figure 1: Chemical structure of marbofloxacin

Clinical Pharmacology

Marbofloxacin is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration to fasted animals. Divalent cations are generally known to diminish the absorption of fluoroquinolones. The effects of concomitant feeding on the absorption of marbofloxacin have not been determined. (See Drug Interactions.) In the dog, approximately 40% of an oral dose of marbofloxacin is excreted unchanged in the urine1. Excretion in the feces, also as unchanged drug, is the other major route of elimination in dogs. Ten to 15% of marbofloxacin is metabolized by the liver in dogs.

In vitro plasma protein binding of marbofloxacin in dogs was 9.1% and in cats was 7.3%. In the cat, approximately 70% of an oral dose is excreted in the urine as marbofloxacin and metabolites with approximately 85% of the excreted material as unchanged drug. Pharmacokinetic parameters related to intravenous dosing were estimated in a study of 6 healthy adult beagle dogs, and are summarized in Table 1. The absolute bioavailability following dosing of oral tablets to the same animals was 94%.

Marbofloxacin plasma concentrations were determined over time in healthy adult beagle dogs (6 dogs per dosage group) following single oral doses of 1.25 mg/lb or 2.5 mg/lb. Absorption of orally administered marbofloxacin increases proportionally over the dose range of 1.25 to 2.5 mg/lb. Marbofloxacin plasma concentrations were determined over time in 7 healthy adult male cats following a single oral dose of 2.5 mg/lb. Plasma pharmacokinetic parameters following oral dosing of dogs and cats are summarized in Figures 2 and 3 and in Table 2. Based on the terminal elimination half-life and the dosing interval, steady-state levels are reached after the third dose and are expected to be approximately 25% greater in dogs and 35% greater in cats than those achieved after a single dose. Marbofloxacin is widely distributed in canine tissues. Tissue concentrations of marbofloxacin were determined in healthy male beagle dogs (4 dogs per time period) at 2, 18 and 24 hours after a single oral dose (1.25 or 2.5 mg/lb) and are summarized in Tables 3a and 3b.

Table 1: Mean pharmacokinetic parameters following intravenous administration of marbofloxacin to 6 adult beagle dogs at a dosage of 2.5 mg/lb.
Parameter

Estimate ± SD*

n=6

Total body clearance, (mL/h•kg) 94 ± 8
Volume of distribution at steady state, VSS, (L/kg) 1.19 ± 0.08
AUC0-inf (µg•h/mL) 59 ± 5
Terminal plasma elimination half-life, t1/2(h) 9.5 ± 0.7
* SD = standard deviation
 
Table 2: Mean pharmacokinetic parameters following oral administration of marbofloxacin tablets to adult beagle dogs at a nominal dosage of 1.25 mg/lb or 2.5 mg/lb and to cats at 2.5 mg/lb.
Parameter

Dog

Estimate ± SD*

(1.25 mg/lb)

n=6

Dog

Estimate ± SD*

(2.5 mg/lb)

n=6

Cat

Estimate ± SD*

(2.5 mg/lb)

n=7

Time of maximum concentration, Tmax (h) 1.5 ± 0.3 1.8 ± 0.3 1.2 ± 0.6
Maximum concentration, Cmax, (µg/mL) 2.0 ± 0.2 4.2 ± 0.5 4.8 ± 0.7
AUC0-inf (µg•h/mL) 31.2 ± 1.6 64 ± 8 70 ± 6
Terminal plasma elimination half-life, t1/2(h) 10.7 ± 1.6 10.9 ± 0.6 12.7 ± 1.1

mean actual dosages administered to dogs were 1.22 mg/lb and 2.56 mg/lb, respectively, and the mean actual dosage administered to cats was 2.82 mg/lb.

* SD = standard deviation

Figure 2: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult beagle dogs at dosages of 1.25 mg/lb or 2.5 mg/lb.

* See Table 4 in Microbiology section for MIC data.

Figure 3: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult cats at a dosage of 2.5 mg/lb.

* See Table 5 in Microbiology section for MIC data.

Table 3a: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 1.25 mg/lb.
 

Marbofloxacin Concentrations

(µg/g ± SD*)

Tissue

2 hours

(n=4)

18 hours

(n=4)

24 hours

(n=4)

bladder 4.8 ± 1.1 2.6 ± 1.5 1.11 ± 0.19
bone marrow 3.1 ± 0.5 1.5 ± 1.5 0.7 ± 0.2
feces 15 ± 9 48 ± 40 26 ± 11
jejunum 3.6 ± 0.5 1.3 ± 1.0 0.7 ± 0.3
kidney 7.1 ± 1.7 1.4 ± 0.5 0.9 ± 0.3
lung 3.0 ± 0.5 0.8 ± 0.2 0.57 ± 0.19
lymph node 5.5 ± 1.1 1.3 ± 0.3 1.0 ± 0.3
muscle 4.1 ± 0.3 1.0 ± 0.3 0.7 ± 0.2
prostate 5.6 ± 1.4 1.8 ± 0.6 1.1 ± 0.4
skin 1.9 ± 0.6 0.41 ± 0.13 0.32 ± 0.08
* SD = standard deviation
 
Table 3b: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 2.5 mg/lb.
  Marbofloxacin Concentrations (µg/g ± SD*)
Tissue

2 hours

(n=4)

18 hours

(n=4)

24 hours

(n=4)

bladder 12 ± 4 6 ± 7 1.8 ± 0.4
bone marrow 4.6 ± 1.5 1.28 ± 0.13 0.9 ± 0.3
feces 18 ± 3 52 ± 17 47 ± 28
jejunum 7.8 ± 1.1 2.0 ± 0.3 1.1 ± 0.3
kidney 12.7 ± 1.7 2.7 ± 0.3 1.6 ± 0.2
lung 5.48 ± 0.17 1.45 ± 0.19 1.0 ± 0.2
lymph node 8.3 ± 0.7 2.3 ± 0.5 2.03 ± 0.06
muscle 7.5 ± 0.5 1.8 ± 0.3 1.20 ± 0.12
prostate 11 ± 3 2.7 ± 1.0 2.0 ± 0.5
skin 3.20 ± 0.33 0.705 ± 0.013 0.46 ± 0.09
* SD = standard deviation

Microbiology: The primary action of fluoroquinolones is to inhibit the bacterial enzyme, DNA gyrase. In susceptible organisms, fluoroquinolones are rapidly bactericidal at relatively low concentrations. Marbofloxacin is bactericidal against a broad range of gram-negative and gram-positive organisms. The minimum inhibitory concentrations (MICs) of pathogens isolated in clinical field studies performed in the United States were determined using National Committee for Clinical Laboratory Standards (NCCLS) standards, and are shown in Tables 4 and 5.

Table 4: MIC Values* (μg/mL) of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs enrolled in clinical studies conducted during 1994-1996.
Organism No. of Isolates MIC50 MIC90 MIC Range
Staphylococcus intermedius 135 0.25 0.25 0.125 - 2
Escherichia coli 61 0.03 0.06 0.015 - 2
Proteus mirabilis 35 0.06 0.125 0.03 - 0.25
Beta-hemolytic Streptococcus, (not Group A or Group B) 25 1 2 0.5 - 16
Streptococcus, Group D enterococcus 16 1 4 0.008 - 4
Pasteurella multocida 13 0.015 0.06 ≤0.008 - 0.5
Staphylococcus aureus 12 0.25 0.25 0.25 - 0.5
Enterococcus faecalis 11 2 2 1 - 4
Klebsiella pneumoniae 11 0.06 0.06 0.01 - 0.06
Pseudomonas spp. 9 ** ** 0.06 - 1
Pseudomonas aeruginosa 7 ** ** 0.25 - 1

Get in touch with us

Enter Your Message